Diamond Capture Associates, a woman-owned business specializing in enterprise technology consulting and large-scale government implementations, and Incode Technologies, a global leader in identity ...
Incode Technologies, the global leader in identity security and fraud prevention, today announced the launch of Deepsight, a breakthrough AI defense that detects and blocks deepfakes, injected virtual ...
GENinCode PLC, up 33% at 3.98 pence, 12-month range 8.50p-1.19p. The genetic testing company says it is collaborating with Thermo Fisher Scientific to sell, distribute and manufacture the Cardo inCode ...
The agreement covers the U.S., Europe, the Middle East, and the African region. CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score (PRS) based on DNA extracted ...
(MENAFN- EIN Presswire) EINPresswire/ -- GENinCode US Inc the Irvine based predictive genetics company focused on the prevention of coronary heart disease (“CHD” or“Heart Disease”) and risk assessment ...
GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of coronary heart disease ("CHD" or "Heart Disease") and risk assessment of ovarian cancer, announces ...
SAN FRANCISCO, December 02, 2025--(BUSINESS WIRE)--Incode Technologies, the global leader in identity security and fraud prevention, today announced the launch of Deepsight, a breakthrough AI defense ...
Incode Technologies Inc., an identity verification platform, is in preliminary talks to raise between $150 million and $300 million from investors at a valuation of as much as $3 billion, according to ...
Investing.com -- Identity verification platform Incode Technologies Inc. is in preliminary discussions to raise between $150 million and $300 million from investors at a valuation of up to $3 billion, ...
SAN FRANCISCO, November 14, 2025--(BUSINESS WIRE)--Incode Technologies (Incode), the global leader in identity security and fraud prevention, today announced that its platform has achieved FedRAMP ...
The study followed over 47,000 individuals of diverse ancestry for 14 years, analysing the relationship between low-density lipoprotein cholesterol (LDL-C) and polygenic risk for CHD. Participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results